Nalaganje...
Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
BACKGROUND: In 2009, the American Society of Clinical Oncology recommended that patients with metastatic colorectal cancer (mCRC) who are candidates for anti-epidermal growth factor receptor (EGFR) therapy have their tumors tested for KRAS mutations because tumors with such mutations do not respond...
Shranjeno v:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3514165/ https://ncbi.nlm.nih.gov/pubmed/23197490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djs433 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|